Open AccessNicotinic Acetylcholine Receptor Expression and Susceptibility to Cholinergic Immunomodulation in Human Monocytes of Smoking Individuals
Author(s) -
Esmerij P. van der Zanden,
Francisca W. Hilbers,
Caroline Verseijden,
René M. van den Wijngaard,
Mike Skynner,
Kevin Lee,
Luis Ulloa,
Guy E. Boeckxstaens,
Wouter J. de Jonge
Publication year - 2012
Publication title -
neuroimmunomodulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.635
H-Index - 65
eISSN - 1423-0216
pISSN - 1021-7401
DOI - 10.1159/000335185
Subject(s) - nicotine , cholinergic , nicotinic agonist , tumor necrosis factor alpha , nicotinic acetylcholine receptor , monocyte , endocrinology , receptor , agonist , biology , medicine , acetylcholine receptor , downregulation and upregulation , immunology , pharmacology , biochemistry , gene
Smoking is generally accepted as a factor that affects the disease course in inflammatory bowel disease patients. Whether these effects can be contributed to the immunomodulatory effects of nicotine via nicotinic acetylcholine receptor (nAChR) activation is unclear. As previous data suggest that the α7 nicotinic acetylcholine receptor (CHRNA7) and its duplicated variant CHRFAM7A may specifically participate in the inflammatory response of monocytes, we evaluated whether repeated nicotine exposure or smoking affects monocyte CHRNA7 and CHRFAM7A expression and cholinergic immunomodulation.